With Three New Partnerships, Adimab Is On Track to Show Discovery Can Pay Off Quickly
This article was originally published in The Pink Sheet Daily
Executive Summary
A growing list of potentially lucrative partnerships has forced a strategic rethink at antibody discovery company Adimab, which plans to return cash to investors in 2011.
You may also be interested in...
Adimab Inks Novo, Biogen Deals, On Track to Double Partnered Programs for Second Straight Year
Antibody discovery outfit Adimab LLC has added two big biotechs to its stable of partners and promises a shift in partnering strategy for 2012.
Adimab Inks Novo, Biogen Deals, On Track to Double Partnered Programs for Second Straight Year
Antibody discovery outfit Adimab LLC has added two big biotechs to its stable of partners and promises a shift in partnering strategy for 2012.
Adimab Inks Merck, Roche Deals and Banks on the Value of Discovery
Adimab, the yeast-based antibody discovery biotech, has signed its first two alliances. In doing so the company revealed to Start-Up its partnering strategy, and discussed why it won't take a single step down the value chain into drug development. Can Adimab make discovery-only work where others have failed?